Company

1990

Eurovalid is founded in Amsterdam, providing compliance and validation services to the pharmaceutical industry.

1995

Eurovalid is incorporated into Eurovalid B.V.

1996

Arthemius v.o.f. was founded, to bring additional expertise for the biotechnology sector.

1997

Eurovalid B.V. and Arthemius v.o.f. internally merge to form Eurovalid-Arthemius B.V.

1998

Helix Engineering B.V. starts collaboration with Eurovalid-Arthemius B.V. to expand the range of services with pharmaceutical engineering.

New activities are employed by starting VipQuip B.V., offering services on metrology and calibration.

Probion B.V., delivering management and business development services to the (bio)pharmaceutical industries, teams up.

1999

Xendo Laboratories B.V., a bioanalytical contract laboratory is founded in Groningen.

2000

The company headquarters move from Amsterdam to the Bio Science Park Leiden.

Univalid Holding B.V. becomes the umbrella company over all operating companies. The names of the different operating companies in Leiden are uniformed:

Eurovalid-Arthemius B.V. changes to Univalid Compliance and Validation B.V.
Helix Engineering B.V. changes to Univalid Engineering B.V.
Probion B.V. changes to Univalid Management and Development B.V.
Vipquip B.V. changes to Univalid Metrology B.V.
Xendo Laboratories B.V. although part of Univalid Holding B.V. keeps its name.

2002

Univalid Holding B.V. acquires a part of Bird Engineering B.V. to form Univalid Bioprocessing B.V.

2004

Xendo Drug Development B.V. expands with Xendo Clinics B.V., a 12-bed Clinical Pharmacology Unit for phase I/IIa clinical research, and Xendo Pharma Design B.V., a consultancy firm focusing on strategic drug research and development, both on the premises of the University Medical Centre Groningen.

Xendo Drug Development B.V., a 100% subsidiary of Univalid Holding B.V., is founded in Groningen, to hold Xendo Laboratories B.V.

Quality Engineering, a business unit of Univalid Engineering B.V. internally merges with Univalid Metrology B.V. to form Univalid Technical Support B.V.

Univalid Bioprocessing B.V. moves its research and pilot laboratories from Delft University to the Bio Science Park in Leiden.

2005

Xendo Clinics B.V. opens a second 14-bed Clinical Pharmacology Unit for phase I/IIa clinical research on the premises of the University Medical Centre Groningen.

2006

As of January 1st, 2006, Univalid Holding B.V. has been restructurered and renamed Xendo B.V. Xendo employs close to 200 people and is comprised of three operational divisions:

Xendo Drug Development B.V.
Xendo Manufacturing B.V.
Xendo Pharma Services B.V.

2007

Xendo B.V. forms a joint venture with the University Medical Center Groningen. The joint venture, Xendo Clinical Trial Material, will produce drug candidates on small scale according to Good Manufacturing Practices.

2008

The Groningen site expands its clinical research portfolio offering (temporary) contract research services in support of phase II – IV studies with drug and medical device candidates. These services are offered through a new division named Xendo Clinical Research.

2009

The Leiden site realigns its structure to better serve our customers. Three divisions were formed, creating a maximal synergy:

Xendo Manufacturing
Xendo Pharma Services
Xendo Regulatory Affairs
Xendo establishes Xendo Deutschland in Berlin, to better meet the needs of German customers. Focus of the German services are on regulatory affairs for drugs and medical devices, from initial set-up to maintenance of dossiers.

2010

As per July 2010 Xendo Drug Development has been acquired by QPS (an international CRO). The Xendo consultancy and manufacturing activities continue under the name Xendo.

2011

Xendo BV and Batavia Bioservices BV have initiated a strategic business collaboration. As a consequence, all Bioprocess activities of Xendo Manufacturing BV have been transferred to Batavia Bioservices BV. Through this collaboration Xendo can continue to offer Bioprocessing services.

2013

Xendo BV has acquired the Vigilex Group allowing Xendo BV to further expand its palette of services with pharmacovigilance activities and at the same time have new branches in the United Kingdom and Japan.

2015

Xendo has acquired Brinker Pharma GmbH allowing Xendo to further expand its presence in the German market offering the full range of consultancy services.

2016

Sovereign Capital, the UK private equity Buy & Build specialist, has completed the management buy-out of Xendo BV. Sovereign has partnered the management team to further develop the business through a strategy of organic and acquisitive growth.

2017

Xendo has acquired the Swedish consultancy company Sofus Regulatory Affairs AB. Sofus is based in Stockholm and provides regulatory affairs services for all phases of the pharma and biotech development, from early development projects to post-approval services including pricing and reimbursement issues, and has a strong position in the Nordic countries.